國立虎尾科技大學 |

Myeloid-derived suppressor cells and cancer

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Myeloid-derived suppressor cells and cancer/ by David Escors ... [et al.].
other author:	Escors, David.
Published:	Cham :Springer International Publishing : : 2016.,
Description:	ix, 102 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Suppressor cells. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-26821-7
ISBN:	9783319268217

Myeloid-derived suppressor cells and cancer
Myeloid-derived suppressor cells and cancer[electronic resource] /by David Escors ... [et al.]. - Cham :Springer International Publishing :2016. - ix, 102 p. :ill., digital ;24 cm. - SpringerBriefs in immunology,2194-2773. - SpringerBriefs in immunology..

Controversies in Neoplastic Myeloplasia -- Differentiation of Murine Myeloid-derived Suppressor Cells -- Human MDSCs -- Ex Vivo MDSC Differentiation Models -- Immunoregulatory myeloid cells in the tumor microenvironment -- Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-derived Suppressor Cells -- Future Perspectives.

The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.

ISBN: 9783319268217

Standard No.: 10.1007/978-3-319-26821-7doiSubjects--Topical Terms:

1106460
Suppressor cells.

LC Class. No.: QR185.8.S96

Dewey Class. No.: 616.079

Myeloid-derived suppressor cells and cancer
LDR:02226nam a2200325 a 4500 001 862826
003 DE-He213
005 20160908163704.0
006 m d
007 cr nn 008maaau
008 170720s2016 gw s 0 eng d
020 $a 9783319268217 $q (electronic bk.)
020 $a 9783319268194 $q (paper)
024 7 $a 10.1007/978-3-319-26821-7 $2 doi
035 $a 978-3-319-26821-7
040 $a GP $c GP
041 0 $a eng
050 4 $a QR185.8.S96
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
082 0 4 $a 616.079 $2 23
090 $a QR185.8.S96 $b M996 2016
245 0 0 $a Myeloid-derived suppressor cells and cancer $h [electronic resource] / $c by David Escors ... [et al.].
260 $a Cham : $c 2016. $b Springer International Publishing : $b Imprint: Springer,
300 $a ix, 102 p. : $b ill., digital ; $c 24 cm.
490 1 $a SpringerBriefs in immunology, $x 2194-2773
505 0 $a Controversies in Neoplastic Myeloplasia -- Differentiation of Murine Myeloid-derived Suppressor Cells -- Human MDSCs -- Ex Vivo MDSC Differentiation Models -- Immunoregulatory myeloid cells in the tumor microenvironment -- Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-derived Suppressor Cells -- Future Perspectives.
520 $a The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.
650 0 $a Suppressor cells. $3 1106460
650 0 $a T cells. $3 669119
650 0 $a Cancer $x Immunotherapy. $3 645557
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Immunology. $3 592892
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Oncology. $3 593951
650 2 4 $a Cell Biology. $3 593889
700 1 $a Escors, David. $3 891044
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a SpringerBriefs in immunology. $3 1064904
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-26821-7
950 $a Biomedical and Life Sciences (Springer-11642)